Chemotherapeutic agents without cross-resistance to prior therapies may enhance PBSC collection and improve patient outcomes by exacting a more potent direct antitumor effect before autologous stem cell transplant. Bendamustine has broad clinical activity in transplantable lymphoid malignancies, but concern remains over the potential adverse impact of this combined alkylator-nucleoside analog on stem cell mobilization. We performed a prospective, nonrandomized phase II study including 34 patients with multiple myeloma (MM) (n = 34; International Staging System (ISS) stages I (35%), II (29%) and III (24%); not scored (13%)) to evaluate bendamustine's efficacy and safety as a stem cell mobilizing agent. Patients received bendamustine (120 mg/m 2 IV days 1, 2), etoposide (200 mg/m 2 IV days 1-3) and dexamethasone (40 mg PO days 1-4) (bendamustine, etoposide and dexamethasone (BED)) followed by filgrastim (10 μg/kg/day SC; through collection). All patients (100%) successfully yielded stem cells (median of 21.60 × 10 6 /kg of body weight; range 9.24-55.5 × 10 6 /kg), and 88% required a single apheresis. Six nonhematologic serious adverse events were observed in 6 patients including: neutropenic fever (1, grade 3), bone pain (1, grade 3) and renal insufficiency (1, grade 1). In conclusion, BED safely and effectively mobilizes hematopoietic stem cells.
INTRODUCTION
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard of care for patients with multiple myeloma (MM). PBSC engraftment occurs more rapidly with infusion of ⩾ 5 × 10 6 CD34+ cells/kg; and 42 × 10 6 CD34+ cells/kg is often considered to be the minimum number of cells required to proceed to SCT. 1, 2 Stem cell proliferation can be enhanced through the addition of myelosuppressive chemotherapy in concert with the hematopoietic cytokine G-CSF. 3 Cyclophosphamide has frequently been used to augment stem cell collection in patients failing G-CSF alone. 4 In patients who have not mobilized adequate CD34+ stem cells with cyclophosphamide, etoposide has been used successfully. 5 However, no single chemotherapy regimen has demonstrated clear superiority for mobilization, and a wide variety of disease-specific cytoreductive chemotherapy approaches have been incorporated into stem cell collection regimens.
The large majority of patients who receive high-dose therapy followed by ASCT for hematologic malignancies have prior exposure to multiple cycles of cytotoxic therapy, sometimes involving numerous regimens. In patients with MM, ASCT is often performed as consolidation after initial cytoreductive chemo/immunotherapy, yet MM patients frequently have persistent measurable disease at the time of PBSC collection. Reducing both disease burden and the level of tumor cell contamination in collected PBSCs has been correlated with reduced rates of relapse and improved outcomes. Unfortunately, prior attempts to purge contaminant tumor cells through CD34 + cell selection have led to delayed immune reconstitution following SCT and an increased rate of viral infection. Impaired T-lymphocyte (T-cell) immunity has been proposed as a mechanism for the increased infectious risk. 6 Chemotherapeutic agents without cross-resistance to prior therapies may enhance PBSC collection and improve patient outcomes by exacting a more potent direct antitumor effect before ASCT. Bendamustine (Treanda; Teva Pharmaceuticals, Petah Tikva, Israel) is a unique synthetic chemotherapeutic compound that combines a bifunctional alkylating nitrogen mustard group and a purine-like benzamidazol nucleus and thus shares structural similarities to both purine analog and alkylating agents without significant cross-resistance to other compounds in either drug class. 7 Although alklyating agents (melphalan, chlorambucil and cyclophosphamide) exhibit similar mechanistic features to one another, bendamustine has a unique mechanism of action 7 and can overcome resistance to melphalan in MM cell lines. 8 Bendamustine has demonstrated activity in a wide range of hematologic malignancies (MM, non-Hodgkin's lymphoma and CLL) and is well tolerated. [9] [10] [11] [12] Bendamustine is approved in the European Community for upfront therapy to treat MM in patients over age 65 years, with neuropathy, who are not considered candidates for ASCT. 13 When combined with high-dose melphalan (200 mg/m 2 ) for myeloablative conditioning in MM, 225 mg/m 2 of bendamustine demonstrated no increased toxicity compared with melphalan alone (200 mg/m 2 ); and a maximum tolerated dose of bendamustine was not reached. 14 As a single agent in the relapsed/refractory setting, bendamustine has demonstrated response rates in 30 to 55% of MM patients, 10, 15 and clinical responses to bendamustinecontaining regimens have been rapid, with a median time to initial response of 31 days in relapsed/refractory MM. 16 The addition of etoposide to mobilization regimens has been shown to increase the overall rate of successful collection, and previous studies have demonstrated that the combination of bendamustine with etoposide is both safe and tolerable. 17 Experience with bendamustine only, combined with dexamethasone followed by G-CSF (BDG) in three patients, 18 did not result in a predictable pattern for leukocyte nadir and recovery. Although all patients treated with the BDG approach were able to eventually collect PBSCs, the variability in time to collection and requirement for frequent monitoring of CD34+ cell levels rendered this approach cumbersome and impractical. Thus, etoposide was combined with bendamustine in the BED (bendamustine, etoposide and dexamethasone) mobilization regimen to ensure a predictable pattern of nadir and subsequent enhanced CD34+ cell expansion phase during recovery.
Bendamustine's potential non-cross-resistance and overall tolerability make it an appealing agent to evaluate for pretransplant cytoreduction. Though bendamustine does not have significant toxicity to stem cells in culture, 19, 20 the immediate impact of bendamustine on PSBC mobilization has not been prospectively evaluated. The limited data on stem cell yield immediately following full-dose bendamustine together with the potential beneficial antitumor effect of this agent provided the scientific rationale for this phase II PBSC mobilization trial in patients with multiple myeloma undergoing ASCT.
MATERIALS AND METHODS
This single-center, open-label prospective trial was open to patients with MM planning to undergo ASCT (six lymphoma patients were also enrolled and will be reported separately). This trial was approved by the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium institutional review board and written informed consent was obtained from all patients. Eligibility criteria included an ECOG (Eastern Cooperative Oncology Group) status o2, absolute neutrophils of ⩾ 1.5 × 10 9 /L, platelets ⩾ 100 × 10 8 /L, creatinine clearance 450 ml/min (Cockcroft-Gault formula), bilirubin o1.5 times the upper limit of normal aspartate transaminase and alanine transaminase o 2.5 times the upper limit of normal. Patients were excluded if they had prior resistance to bendamustine, ⩾ 4 prior different myelotoxic chemotherapy regimens (for example, VRD-PACE (bortezomib/lenalidomide/dexamethasone/ cisplatin/doxorubicin/cyclophosphamide/etoposide)), symptomatic cardiopulmonary disease, fludarabine therapy in the preceding 24 months, ⩾ 7 cycles of lenalidomide, a prior failed stem cell mobilization attempt, prior autologous or allogeneic SCT, known HIV, hepatitis B or C, 43 cycles of multi-agent myelotoxic salvage chemotherapy within 4 months of enrollment, prior pelvic/spinal irradiation or systemic chemotherapy within 3 weeks of initiating BED.
Study design
Patients were administered 1 cycle of BED (bendamustine (120 mg/m 2 IV days 1, 2), etoposide (200 mg/m 2 IV days 1-3) and dexamethasone (40 mg PO days 1-4), delivered as an outpatient, followed by filgrastim (initially 10 μg/kg/day SC; starting on day 5 through end of collection)). Apheresis was initiated when peripheral blood CD34+ cell counts were 45/μL. The primary end point was successful mobilization in over 80% of patients, defined as collection of ⩾ 2.0 × 10 6 CD34+ cells/kg. The stem cell mobilization success rate after chemotherapy regimens has typically been ⩾ 80%. 2, 5, 21 This study was not powered to observe a rate that is statistically significantly better than 80%, as such a study would have required a very large number of patients. Rather, potential efficacy was defined by identifying an observed collection success rate of at least 80%. A total of 40 patients were enrolled (including the 6 lymphoma patients to be reported elsewhere), and if the true success rate was 70%, then the probability of seeing 32 or more successes among 40 patients (an observed rate of 80% or more) was 0.11. An observed rate of 80% provides 89% confidence that the true success rate is over 70%. We considered any outcome of 480% successful mobilization to be sufficiently consistent with an acceptable success rate that the regimen could be considered potentially efficacious. Adverse events were graded using the CTCAE (Common Terminology Criteria for Adverse Events) v4.0. Secondary end points included determining the number of apheresis cycles required to collect a minimum of 42 × 10 6 CD34+ cells/kg and ideally 45 × 10 6 CD34+ cells/kg, and evaluation of the disease response rate to one cycle of BED. Vital signs and clinical status were closely monitored during bendamustine infusion. Tumor lysis syndrome associated with bendamustine treatment has been reported, and volume status, serum chemistries and uric acid levels were monitored. Patients deemed to be at risk for tumor lysis syndrome who received prophylactic allopurinol were monitored closely, as some investigators have suggested an increased risk for severe skin toxicity when bendamustine is combined with allopurinol. 22 When patients' absolute neutrophil counts dropped below 500 mm 3 , prophylactic antibiotic therapy (fluoroquinolone) was initiated at the discretion of the treating physician.
Response criteria
Response in patients with measurable disease was a secondary end point and was assessed after a single cycle of BED. Definitions of disease, criteria for evaluation, end point definitions and response criteria were defined by the multiple myeloma response criteria as defined by the International Multiple Myeloma Working Group. 23, 24 
RESULTS

Patient characteristics
We enrolled 34 MM patients in this trial between May 2011 and October 2013. Patient characteristics are shown in Table 1 . Patients were a median age of 61 years (range 46-70). The MM patients received a median of one line of prior therapy (range 1-3) with 22 receiving a median of 4 cycles of lenalidomide-based therapy (range 1-6). Twenty-six patients received one line of prior therapy. Six patients received either two (n = 4) or three (n = 2) lines of therapy before stem cell mobilization ( Table 2 ). More than one regimen was administered to deepen disease response before ASCT (n = 3), in response to intolerance to the prior regimen (n = 2) or because of a change in treatment plan (n = 1; after once cycle of melphalan containing therapy, the treatment goal were modified to include ASCT). International Staging System (ISS) scores could be calculated for 31/34 MM patients from the time of diagnosis; 12 patients were stage I, 10 were stage II and 9 were stage III. Eight of the 34 MM patients had high-risk cytogenetic features identified either by conventional cytogenetic analysis or by MM-specific FISH probes. These high-risk features included t(4;14) (3 patients); 17p-(3 patients); t(14;16) (2 patients); complex karyotype (1 patient); 1p-(1 patient) including 2 patients demonstrating 2 high-risk features concurrently. Two patients had received prior radiotherapy. Twenty-six patients had measurable disease before BED. Thirty-one patients have proceeded to ASCT following collection.
Stem cell mobilization and collection
All MM patients (34/34) were successfully mobilized. No patient required dose reduction of the chemotherapy agents. The median number of CD34 + cells collected was 21.60 × 10 6 /kg (range 9.24 to 55.51 × 10 6 , Figure 1a ). A sufficient number of CD34+ cells for two future ASCTs were collected from all subjects including 33 of 34 (97%) collecting ⩾ 10 × 10 6 CD34 + cells/kg and all yielding ⩾ 9 × 10 6 CD34 + cells/kg. Twenty-two MM patients received lenalidomide therapy before mobilization, and there was no difference in the absolute number of CD34+ stem cells collected after BED among those who had received p4 cycles of lenalidomide (21.64 × 10 6 CD34+ cells/kg, n = 13) and those treated with 44 but o 7 cycles of lenalidomide (20.8 × 10 6 CD34+ cells/kg, n = 9) (P = 0.98). The median time from the start of BED mobilization therapy to the first day of CD34+ stem cell collection was 11 days (range 9-13 days, Figure 1b ). The median number of apheresis days was 1 (range 1-4, Figure 1c ). A predictable pattern of leukocyte nadir and recovery was demonstrated (all patients started apheresis between days 9 and 13). One patient (3%) was given plerixafor (administered at the discretion of the transplant service attending physician of record) on day 12 after BED. This patient was defined as a 'collection failure' based on the prespecified goal of achieving adequate collection without requiring plerixafor support; however, the patient was successfully mobilized and collected 13.45 × 10 6 CD34+ cells/kg over 3 days. Time to collection, days of apheresis and number of stem cells collected for this patient were not included in the study collection results because plerixafor represents a variable that was not equally applied to all study participants and the decision to use plerixafor was based on the clinical judgment of the transplant attending of record; however, the subject was not excluded from the response assessment. This patient had previously received 6 cycles of bortezomib/ cyclophosphamide/dexamethasone and had previously required bortezomib dose reductions because of cytopenias. In 1 MM patient (3%) the G-CSF dose was increased to 16 μg/kg twice daily in response to prolonged neutrophil recovery. This patient had previously received 3 cycles of cyclophosphamide/liposomal doxorubicin/bortezomib/dexamethasone therapy; 4 cycles of bortezomib/thalidomide/dexamethasone; and one cycle of VRD-PACE. Among the 21 evaluable patients ⩾ 60 years of age, the mean number of CD34+ cells/kg was 23.01 × 10 6 (SD 11.80), and for the 12 patients aged o 60 years, the mean number was 27.21 × 10 6 (SD 15.47, P = 0.38; the plerixafor-treated patient was 61 years old, yielded 13.45 × 10 6 and was not included in the analysis).
Among the 30 MM patients with ISS scores available from diagnosis, there was no correlation between ISS and median number of stem cells/kg mobilized (25.96 × 10 6 for stage I (n = 12), 19.82 × 10 6 for stage II (n = 10) and 20.79 × 10 6 for stage III (n = 9)), and no relationship between stem cell yield and the presence of high-risk cytogenetic features.
Toxicity and engraftment Expected grade 3 or 4 thrombocytopenia, leukopenia and lymphopenia were seen in most patients ( Table 3 ). Six serious adverse events were observed in six patients. Serious adverse events included: neutropenic fever (1, grade 3), bone pain (1, grade 3), renal insufficiency (1, grade 1), atrial fibrillation (1, grade 2), hypotension (1, grade 3) and stroke (1, grade 2). Among the 34 patients mobilized and collected, 31 have thus far undergone ASCT, and 100% (31/31) achieved an unsupported neutrophil count ⩾ 500/μL at a median of 15 days (range 7-19, Figure 2a ) after PBSC infusion and a platelet count ⩾ 20K/μL at a median of 11 days (range 8-15, Figure 2b ).
Response rates
Responses among all 34 patients were evaluated and include: CR = 4, very good PR = 0, PR = 6, stable disease = 22 and progressive disease = 2. The overall response rate to this single cycle of therapy was 29%. Response was measured in MM patients at a median of 26.5 days (range 10-69) after initiating BED. Two of the 9 MM patients (22%) with high-risk cytogenetic were in a CR after one cycle of BED. Eleven of the 34 MM patients had no evidence of bone marrow involvement at enrollment and 8 had no measurable monoclonal protein. Among the 4 patients in CR, 3 had a CR and 1 a PR to their most recent regimen before BED mobilization. Among the 6 patients with PR, 4 had a PR, 1 a CR and 1 was not evaluable for response to their most recent regimen. Among the 22 patients with stable disease after BED, 1 was in very good PR, 1 in CR, 1 with stable disease, 18 with a PR and 1 was not evaluable for response to their most recent treatment regimen. Among the 2 patients with progressive disease, 1 had stable disease and 1 a PR to their most recent pre-BED regimen.
DISCUSSION
Important considerations in selecting an effective stem cell chemotherapy-based mobilization regimen for MM include: (1) non-cross-resistance with prior therapies, (2) the potency of a single cycle of treatment, (3) capacity for predictable robust CD34+ cell mobilization (facilitating short apheresis duration and cost containment) and (4) safety. Recent consensus guidelines addressing stem cell collection approaches advocate for the identification of novel mobilization strategies designed to improve yields, efficiency and cost. 25, 26 This study demonstrates that BED mobilization offers advantages in each of these categories.
Cyclophosphamide is the most frequently used chemomobilization agent in MM. Cyclophosphamide can effectively increase CD34+ cell yields; [27] [28] [29] however cyclophosphamide mobilization does not improve rates of CR, time to progression, event-free survival or overall survival in MM, whereas the risk of developing bacteremia is increased when compared with G-CSF mobilization alone. 30 This absence of a documented antitumor effect, in conjunction with increased cost and toxicity, has led some groups to recommend limiting chemotherapy-based mobilization to MM patients presenting with circulating plasma cells or disease in frank relapse. 31 Identifying an alternative mobilization regimen capable of safely improving disease control in MM patients may be important however, because disease control pretransplant has been associated with improvements in long-term patient outcomes, 32 and achieving a CR or stringent CR after high-dose therapy ASCT has been shown to significantly improve event-free survival, PFS and overall survival. [33] [34] [35] The time to response is an important consideration when selecting non-cross-resistant mobilization regimens designed to reduce disease burden, because the time window between stem cell mobilization and subsequent myeloablative conditioning therapy is frequently short. When bendamustine was compared with oral melphalan (both in combination with prednisone) in newly diagnosed MM patients, bendamustine demonstrated a significantly faster time for maximum response and had a longer time to treatment failure (14 vs 10 months, P o 0.02). 11 Measurable responses to a single cycle of bendamustine-based therapy have been reported at a median 31 days after treatment among patients with relapsed or refractory MM (⩾ PR, for bendamustine combined with bortezomib and dexamethasone among MM patients (63% with prior bortezomib treatment)), and an overall response rate of 61% was reported in this heavily pretreated patient population. 16 Rapid responses have also been reported when bendamustine is combined with lenalidomide and dexamethasone in patients with relapsed or refractory MM. 36, 37 In our study, 31 patients proceeded to ASCT within 3 months of study enrollment. Of necessity, restaging was performed a median of only 26.5 days (range 10-69) after BED. The short time interval between treatment and disease response assessment may contribute to an underestimation of MM response rates in this study, because established MM response criteria are reliant on serologic markers that lack short-term sensitivity 23, 24 (the clearance half-life for IgG monoclonal protein is 43 weeks). 38 Following ASCT, improved outcome has been associated with time to engraftment of platelets, neutrophils and lymphocytes, and the time to recovery has correlated with stem cell dose. 39, 40 Patients receiving BED mobilization yielded a median of 21.60 ×10 6 CD34+ stem cells (mean 24.53; range 9.24-55.5 × 10 6 ). The absolute number of CD34+ cells collected after cyclophosphamide alone, or in combination with etoposide mobilization, is variable (see Table 4 ) and reflects differences in patient populations on clinical trials. Although different study populations make comparisons of CD34+ cell yield between trials less informative, some studies have suggested that cyclophosphamide-based regimens impair stem cell engraftment, 27 whereas with BED, engraftment is rapid ( Figure 2) .
Advanced age has been associated with inferior CD34+ cell collection yields with other mobilization regimens, 39, 40 but among patients receiving BED there was no significant difference in stem cell collection yield between patients aged ⩾ 60 years (mean = 23.01 × 10 6 CD34/kg (SD 11.80)) and those aged o 60 years (27.21 × 10 6 CD34/kg (SD 15.47, P = 0.38)). Although the findings reported here for BED mobilization are encouraging, results from this trial should be further evaluated in a phase III randomized mobilization study comparing BED with a Cytoxan-containing regimen. Extrapolation of the current results to the general ASCT patient population is limited by the study's enrollment criteria. To assess safety and efficacy associated with a bendamustine-containing regimen, the trial design necessarily excluded patients who had received prior radiation to bone marrow, seven or more cycles of lenalidomide and significant exposure to myelotoxic regimens. Although data in these populations would be clinically useful, inclusion of such patients would have limited our capacity to evaluate the impact of the BED regimen on stem cell mobilization. As a result, the population described herein does not fully represent the spectrum of patients Abbreviations: BED = bendamustine, etoposide and dexamethasone; CY = cyclophosphamide; MM = multiple myeloma; NHL = non-Hodgkin's lymphoma; NR = not reached.
Bendamustine regimen to mobilize stem cells DJ Green et al who may benefit from BED. The finding that stem cell yield after BED was not impaired among patients who had previously received up to six prior cycles of lenalidomide was encouraging, as some groups have reported decreased CD34+ stem cell yields after more than four prior cycles of lenalidomidecontaining therapy. 41 Although etoposide likely contributed to the efficacy of the BED regimen, this study validates the safety of a bendamustine and etoposide combination for mobilization. Moreover, the singleagent activity of etoposide in MM is limited, and bendamustine represents a non-cross-resistant agent capable of improving disease response rates. Recent studies have demonstrated synergy between the proteasome inhibitor bortezomib and bendamustine, suggesting the possibility that a four-agent bendamustinecontaining mobilization regimen could further improve response rates. 42 In conclusion, bendamustine does not appear to be an acute stem cell toxin and PBSC mobilization with BED is safe and effective. Large numbers of stem cells were rapidly mobilized and resulted in short durations of apheresis. No patient yielded fewer than 9 × 10 6 CD34 + cells/kg (sufficient for 2 ASCTs). In patients who were transplanted, the time to neutrophil and platelet engraftment was comparable to other chemotherapybased mobilization regimens. The BED regimen was well tolerated and these findings suggest a role for BED in PBSC mobilization.
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